SCHEMBL5534166

SCHEMBL5534166

N#CCNC(=O)C(CNC(=O)c1ccc(N)cc1)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSL P07711 9/20 0.55
CTSK P43235 6/20 0.48
CTSB P07858 5/20 0.48
CTSS P25774 5/20 0.48
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HIF1A Q16665 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
ITGB3 P05106 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGAV P06756 1/20 0.39
ITGA5 P08648 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CXCR4 P61073 1/20 0.39
ALOX15 P16050 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5522184 0.90 CTSL (0.56) CTSLCTSKCTSBCTSSNPC1
SCHEMBL5521620 0.90 CTSL (0.56) CTSLCTSKCTSBCTSSNPC1
SCHEMBL5525342 0.90 CTSL (0.60) CTSLCTSKCTSBCTSSRAB9A
SCHEMBL5534185 0.89 CTSL (0.55) CTSLCTSKCTSBCTSSNPC1
SCHEMBL5529606 0.89 CTSL (0.55) CTSLCTSKCTSBCTSSNPC1
SCHEMBL5525765 0.89 CTSL (0.71) CTSLCTSKCTSBCTSSNPC1
SCHEMBL5527661 0.88 CTSL (0.57) CTSLCTSKCTSBCTSS
SCHEMBL5522994 0.87 CTSL (0.47) CTSLCTSKCTSBCTSSRAB9A
SCHEMBL5526314 0.87 CTSL (0.53) CTSLCTSKCTSBCTSSKDM4E
SCHEMBL5527570 0.87 CTSL (0.53) CTSLCTSKCTSBCTSSNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-20030096796-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-05-22 US disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096796-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSL 14/4885CTSK 32/4885CTSB 11/4885
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSL 14/4885CTSK 32/4885CTSB 11/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 CTSL 14/4885CTSK 32/4885CTSB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.